ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $627,263 | -17.9% | 30,099 | -5.6% | 0.01% | -16.7% |
| Q2 2023 | $763,933 | +15.3% | 31,897 | -9.4% | 0.01% | 0.0% |
| Q1 2023 | $662,276 | +21.5% | 35,190 | +2.7% | 0.01% | +20.0% |
| Q4 2022 | $545,276 | +1.4% | 34,251 | +4.1% | 0.01% | -16.7% |
| Q3 2022 | $538,000 | +17.0% | 32,901 | +0.7% | 0.01% | +50.0% |
| Q2 2022 | $460,000 | -41.7% | 32,674 | +0.3% | 0.00% | -33.3% |
| Q1 2022 | $789,000 | +4.2% | 32,591 | +0.5% | 0.01% | 0.0% |
| Q4 2021 | $757,000 | +39.2% | 32,427 | -0.9% | 0.01% | +50.0% |
| Q3 2021 | $544,000 | -31.7% | 32,724 | +0.3% | 0.00% | -33.3% |
| Q2 2021 | $796,000 | -11.1% | 32,629 | -6.0% | 0.01% | -25.0% |
| Q1 2021 | $895,000 | -51.5% | 34,709 | +0.5% | 0.01% | -52.9% |
| Q4 2020 | $1,847,000 | +26.9% | 34,551 | -2.0% | 0.02% | +21.4% |
| Q3 2020 | $1,455,000 | +14.1% | 35,270 | +34.1% | 0.01% | -22.2% |
| Q2 2020 | $1,275,000 | +11.3% | 26,296 | -3.0% | 0.02% | -10.0% |
| Q1 2020 | $1,146,000 | – | 27,120 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |